Roivant Sciences (NASDAQ:ROIV) Director Sells $17,933,049.24 in Stock

by · The Markets Daily

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $23.07, for a total transaction of $17,933,049.24. Following the completion of the sale, the director directly owned 16,353,113 shares of the company’s stock, valued at $377,266,316.91. The trade was a 4.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Daniel Allen Gold also recently made the following trade(s):

  • On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The shares were sold at an average price of $23.04, for a total transaction of $21,134,177.28.
  • On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.23, for a total transaction of $26,299,000.00.

Roivant Sciences Stock Performance

Shares of ROIV traded down $0.91 during trading hours on Thursday, hitting $21.79. The stock had a trading volume of 8,173,006 shares, compared to its average volume of 7,547,139. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $23.47. The firm has a market cap of $15.15 billion, a P/E ratio of -38.91 and a beta of 1.22. The company’s fifty day simple moving average is $19.88 and its 200 day simple moving average is $14.99.

Institutional Trading of Roivant Sciences

Institutional investors have recently modified their holdings of the company. Allworth Financial LP lifted its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new position in Roivant Sciences in the third quarter valued at about $217,000. Danske Bank A S acquired a new position in Roivant Sciences in the 3rd quarter worth about $138,000. XTX Topco Ltd purchased a new stake in shares of Roivant Sciences during the 3rd quarter worth about $1,067,000. Finally, Alyeska Investment Group L.P. grew its stake in shares of Roivant Sciences by 326.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 494,455 shares of the company’s stock valued at $7,481,000 after buying an additional 378,589 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the subject of several recent research reports. Leerink Partners increased their price objective on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price target on shares of Roivant Sciences in a report on Thursday. Bank of America raised their target price on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research note on Thursday, September 18th. Citigroup upped their target price on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.19.

Read Our Latest Research Report on ROIV

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

See Also